Pharmacokinetic Analysis of Nicotinamide Riboside
Sponsor: Aarhus University Hospital
Collaborator: University of Copenhagen
Purpose
Nicotinamide riboside is a newly discovered vitamin B3. The pharmacokinetics in humans is so far not analyzed.
Study Design
Open leabel, 2 dose cross-over
Dose
500mg or 1000mg
Length of Intervention
Single dose
Status
Completed
Condition or Disease
Healthy Participants
Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.